Portage Biotech Inc. (NASDAQ:PRTG) Sees Significant Increase in Short Interest

Portage Biotech Inc. (NASDAQ:PRTG) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 22,800 shares, an increase of 15.2% from the January 15th total of 19,800 shares. Based on an average daily trading volume, of 653,800 shares, the days-to-cover ratio is currently 0.0 days. Approximately 5.2% of the company’s stock are sold short.

Portage Biotech Stock Performance

PRTG stock opened at $4.61 on Monday. The company’s 50 day moving average price is $4.74 and its 200 day moving average price is $4.83. Portage Biotech has a fifty-two week low of $2.10 and a fifty-two week high of $23.01.

Portage Biotech (NASDAQ:PRTG) last announced its quarterly earnings data on Tuesday, November 26th. The company reported ($1.26) EPS for the quarter.

Institutional Trading of Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Sanctuary Advisors LLC acquired a new position in shares of Portage Biotech Inc. (NASDAQ:PRTG) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 297,728 shares of the company’s stock, valued at approximately $63,000. Sanctuary Advisors LLC owned approximately 28.36% of Portage Biotech as of its most recent filing with the SEC. 13.36% of the stock is owned by institutional investors.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.